EXECUTIVE ENGAGEMENTS
POOL
686
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
137
Interactions with Platform & by Email
PARTICIPANTS
27
Unique # Participated
VALIDATIONS
11
Responses Validated*
COMPANIES
46
Responses Validated*
* Login for a full stack data experience
DATE
OCT 2022
TABLES
123
PAGES
196
EDITION
9
PRICE
USD 4950
CODE
MCP16833
*Engagement stats are ongoing and dynamic
RESEARCH MODULES
EXECUTIVES
HIGHLIGHTS & REPORT INDEX
Amid the COVID-19 crisis, the global market for Subcutaneous Immunoglobulin estimated at US$3.8 Billion in the year 2020, is projected to reach a revised size of US$9.3 Billion by 2027, growing at aCAGR of 13.5% over the period 2020-2027. Primary Immunodeficiency Diseases, one of the segments analyzed in the report, is projected to record 14.6% CAGR and reach US$7 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Secondary Immunodeficiency Diseases segment is readjusted to a revised 10.5% CAGR for the next 7-year period.
The Subcutaneous Immunoglobulin market in the U.S. is estimated at US$1.1 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2027 trailing a CAGR of 12.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 11.8% and 11.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 9.8% CAGR.
SELECT PLAYERS
Biotest AG; CSL Behring; Grifols International SA; Grifols SA; Kedrion SpA; Octapharma AG; Shire PLC
SEGMENTS
» Application (Primary Immunodeficiency Diseases, Secondary Immunodeficiency Diseases) » End-Use (Hospitals, Clinics, Homecare Settings)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Current & Future Analysis for Subcutaneous Immunoglobulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Subcutaneous Immunoglobulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Subcutaneous Immunoglobulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Primary Immunodeficiency Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Primary Immunodeficiency Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Primary Immunodeficiency Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Secondary Immunodeficiency Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Secondary Immunodeficiency Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Secondary Immunodeficiency Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Homecare Settings by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Homecare Settings by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Homecare Settings by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| USA Current & Future Analysis for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Subcutaneous Immunoglobulin by Application - Percentage Breakdown of Value Sales for Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases for the Years 2012, 2020 & 2027 |
| USA Current & Future Analysis for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Subcutaneous Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2012, 2020 & 2027 |
| CANADA |
| Canada Current & Future Analysis for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Subcutaneous Immunoglobulin by Application - Percentage Breakdown of Value Sales for Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases for the Years 2012, 2020 & 2027 |
| Canada Current & Future Analysis for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Subcutaneous Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2012, 2020 & 2027 |
| JAPAN |
| Japan Current & Future Analysis for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Subcutaneous Immunoglobulin by Application - Percentage Breakdown of Value Sales for Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases for the Years 2012, 2020 & 2027 |
| Japan Current & Future Analysis for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Subcutaneous Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2012, 2020 & 2027 |
| CHINA |
| China Current & Future Analysis for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Subcutaneous Immunoglobulin by Application - Percentage Breakdown of Value Sales for Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases for the Years 2012, 2020 & 2027 |
| China Current & Future Analysis for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Subcutaneous Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2012, 2020 & 2027 |
| EUROPE |
| Europe Current & Future Analysis for Subcutaneous Immunoglobulin by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Subcutaneous Immunoglobulin by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Subcutaneous Immunoglobulin by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Subcutaneous Immunoglobulin by Application - Percentage Breakdown of Value Sales for Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases for the Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Subcutaneous Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2012, 2020 & 2027 |
| FRANCE |
| France Current & Future Analysis for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Subcutaneous Immunoglobulin by Application - Percentage Breakdown of Value Sales for Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases for the Years 2012, 2020 & 2027 |
| France Current & Future Analysis for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Subcutaneous Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2012, 2020 & 2027 |
| GERMANY |
| Germany Current & Future Analysis for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Subcutaneous Immunoglobulin by Application - Percentage Breakdown of Value Sales for Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases for the Years 2012, 2020 & 2027 |
| Germany Current & Future Analysis for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Subcutaneous Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2012, 2020 & 2027 |
| ITALY |
| Italy Current & Future Analysis for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Subcutaneous Immunoglobulin by Application - Percentage Breakdown of Value Sales for Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases for the Years 2012, 2020 & 2027 |
| Italy Current & Future Analysis for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Subcutaneous Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2012, 2020 & 2027 |
| UNITED KINGDOM |
| UK Current & Future Analysis for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Subcutaneous Immunoglobulin by Application - Percentage Breakdown of Value Sales for Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases for the Years 2012, 2020 & 2027 |
| UK Current & Future Analysis for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Subcutaneous Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2012, 2020 & 2027 |
| REST OF EUROPE |
| Rest of Europe Current & Future Analysis for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Subcutaneous Immunoglobulin by Application - Percentage Breakdown of Value Sales for Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases for the Years 2012, 2020 & 2027 |
| Rest of Europe Current & Future Analysis for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Subcutaneous Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2012, 2020 & 2027 |
| ASIA-PACIFIC |
| Asia-Pacific Current & Future Analysis for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Subcutaneous Immunoglobulin by Application - Percentage Breakdown of Value Sales for Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases for the Years 2012, 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Subcutaneous Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2012, 2020 & 2027 |
| REST OF WORLD |
| Rest of World Current & Future Analysis for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Subcutaneous Immunoglobulin by Application - Percentage Breakdown of Value Sales for Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases for the Years 2012, 2020 & 2027 |
| Rest of World Current & Future Analysis for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Subcutaneous Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2012, 2020 & 2027 |
| IV. COMPETITION |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com